| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Testis |
BIOQUAL, Inc., Rockville, Maryland 20850
Intratesticular testosterone (ITT) is known to play a critical role in the maintenance of spermatogenesis. We have used acyline, a GnRH antagonist, to suppress testosterone (T) production, and acyline and T implants to study the prevention of irreversible infertility induced by CDB-4022. Vehicle or acyline was administered to proven fertile male rats (n = 5/group) at a dose (210 µg/day) that completely suppressed (P < 0.05) T production, as measured by serum T, and testicular function, either before, concurrent with, or after vehicle or a single oral dose of 2.5 mg CDB-4022/kg (Week 0). Vehicle-treated males remained fertile, whereas acyline-treated males exhibited transitory infertility. CDB-4022 alone caused irreversible infertility in all males. Importantly, CDB-4022-treated males recovered fertility when acyline was started before CDB-4022 (Weeks –4 to 0; Weeks –4–9), but not when acyline was administered concurrently with or after CDB-4022 (Weeks 0–9; Weeks 10–19). At the end of this study (Week 34), testes weights, spermatid head counts (SHC), and tubule differentiation indices (TDI) were suppressed (P < 0.05) in infertile CDB-4022-treated males, but in rats that recovered fertility, these parameters were similar (P > 0.05) to those in vehicle-treated males. In addition, serum inhibin B and epididymal androgen-binding protein levels were nondetectable in infertile CDB-4022-treated rats. To test whether suppression of ITT was critical for prevention of CDB-4022-induced infertility, proven fertile rats (n = 7–8/group) received vehicle, acyline alone, or acyline and a T implant for 4 wk before CDB-4022 (Week 0). The T implant increased ITT in acyline-treated rats. Although ITT was lower (P < 0.05) in the T-implanted males than in untreated rats, it was sufficient to sustain spermiogenesis. Serum rFSH levels were also elevated in rats treated with acyline + T as compared with acyline alone during the treatment interval, but rFSH was still lower than in vehicle-treated rats. Rats in all treatment groups were rendered infertile initially, but the acyline + CDB-4022-treated rats recovered fertility by Week 10. In contrast, rats treated with CDB-4022 alone or acyline + T + CDB-4022 remained infertile until at least Week 16. Testes weights, SHC, and TDI were within normal ranges for acyline + CDB-4022-treated rats, but were decreased (P < 0.05) in CDB-4022- or acyline + T + CDB-4022-treated rats. Serum inhibin B levels were nondetectable by Week 1 in males rendered irreversibly infertile by CDB-4022; levels increased transiently and returned to baseline in rats protected by acyline pretreatment. These data indicate that pretreatment with acyline was able to prevent irreversible infertility in CDB-4022-treated rats, whereas posttreatment with acyline did not promote spermatogonial differentiation, as has been observed by others in rats that received GnRH analogs and various other testicular toxicants. Suppression of ITT and possibly rFSH by acyline appeared to be crucial in preventing irreversible infertility induced by CDB-4022. In this regard, our results are similar to those of investigators who have studied other testicular toxicants. Continued development of CDB-4022 as a potential male contraceptive will depend largely on its safety profile and whether its antispermatogenic activity is reversible in primates.
2 Correspondence: Sheri Hild, BIOQUAL, Inc., 9600 Medical Center Dr., Rockville, MD 20850. FAX: 301/251-1260; shild{at}bioqual.com
This article has been cited by other articles:
|
|
 |
|
  S. T. Page, J. K. Amory, and W. J. Bremner Advances in Male Contraception Endocr. Rev., June 1, 2008; 29(4): 465 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Mruk, B. Silvestrini, and C. Y. Cheng Anchoring Junctions As Drug Targets: Role in Contraceptive Development Pharmacol. Rev., June 1, 2008; 60(2): 146 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Tash, B. Attardi, S. A. Hild, R. Chakrasali, S. R. Jakkaraj, and G. I. Georg A Novel Potent Indazole Carboxylic Acid Derivative Blocks Spermatogenesis and Is Contraceptive in Rats after a Single Oral Dose Biol Reprod, June 1, 2008; 78(6): 1127 - 1138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Koduri, S. A. Hild, L. Pessaint, J. R. Reel, and B. J. Attardi Mechanism of Action of l-CDB-4022, a Potential Nonhormonal Male Contraceptive, in the Seminiferous Epithelium of the Rat Testis Endocrinology, April 1, 2008; 149(4): 1850 - 1860. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-C. Chen, R. K Cochrum, M. T Tseng, D. T Ghooray, J. P Moore, S. J Winters, and B. J Clark Effects of CDB-4022 on Leydig Cell Function in Adult Male Rats Biol Reprod, December 1, 2007; 77(6): 1017 - 1026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Hild, J. R. Reel, M. J. Dykstra, P. C. Mann, and G. R. Marshall Acute Adverse Effects of the Indenopyridine CDB-4022 on the Ultrastructure of Sertoli Cells, Spermatocytes, and Spermatids in Rat Testes: Comparison to the Known Sertoli Cell Toxicant Di-n-pentylphthalate (DPP) J Androl, July 1, 2007; 28(4): 621 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Hild, G. R. Marshall, B. J. Attardi, R. A. Hess, S. Schlatt, D. R. Simorangkir, S. Ramaswamy, S. Koduri, J. R. Reel, and T. M. Plant Development of l-CDB-4022 as a Nonsteroidal Male Oral Contraceptive: Induction and Recovery from Severe Oligospermia in the Adult Male Cynomolgus Monkey (Macaca fascicularis) Endocrinology, April 1, 2007; 148(4): 1784 - 1796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Porter, G. Shetty, and M. L. Meistrich Testicular Edema Is Associated with Spermatogonial Arrest in Irradiated Rats Endocrinology, March 1, 2006; 147(3): 1297 - 1305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Boekelheide, H. A. Schoenfeld, S. J. Hall, C. C. Weng, G. Shetty, J. Leith, J. Harper, M. Sigman, D. L. Hess, and M. L. Meistrich Gonadotropin-Releasing Hormone Antagonist (Cetrorelix) Therapy Fails to Protect Nonhuman Primates (Macaca arctoides) From Radiation-Induced Spermatogenic Failure J Androl, March 1, 2005; 26(2): 222 - 234. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
